Feb 6 (Reuters) - Medical device maker Zimmer Biomet

Holdings ( ZBH ) forecast full-year adjusted profit below Wall

Street estimates on Thursday, as it anticipates a hit from a

strong dollar.

The company expects 2025 adjusted profit to be in the range

of $8.15 to $8.35 per share, compared with the average of

analysts' expectations of $8.56 per share, according to data

compiled by LSEG. The company expects a 1.5% to 2% negative

impact from currency swings on its revenue this year.

However, the company's fourth-quarter profit and revenue

both came in slightly above expectations, due to strong demand

for its devices used in hip and knee procedures.

Combined sales at Zimmer's hips and knees units came in at

$1.36 billion, compared to $1.30 billion, a year ago.

Sales at its unit that sells sports medicine and trauma care

products came in at $489.4 million, compared to $453.3 million,

a year ago.

Brokerage Evercore ISI says that the forecast is already

lower than expected and Zimmer's acquisition of orthopedic

surgical devices maker Paragon 28 ( FNA ), announced last month,

could further reduce earnings by another 10 cents.

In the fourth quarter, the company posted a profit of $2.31

per share, beating estimates by 1 cent.

Zimmer's total sales for the reported quarter came in at

$2.02 billion, compared with analysts' estimates of $2.01

billion.